DK0871440T3 - Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister - Google Patents
Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonisterInfo
- Publication number
- DK0871440T3 DK0871440T3 DK96941518T DK96941518T DK0871440T3 DK 0871440 T3 DK0871440 T3 DK 0871440T3 DK 96941518 T DK96941518 T DK 96941518T DK 96941518 T DK96941518 T DK 96941518T DK 0871440 T3 DK0871440 T3 DK 0871440T3
- Authority
- DK
- Denmark
- Prior art keywords
- schizophrenia
- negative
- treatment
- cognitive symptoms
- glycine uptake
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title abstract 4
- 239000004471 Glycine Substances 0.000 title abstract 2
- 201000000980 schizophrenia Diseases 0.000 title abstract 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US836195P | 1995-12-07 | 1995-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0871440T3 true DK0871440T3 (da) | 2006-07-10 |
Family
ID=21731199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96941518T DK0871440T3 (da) | 1995-12-07 | 1996-12-05 | Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister |
Country Status (10)
Country | Link |
---|---|
US (3) | US5854286A (de) |
EP (1) | EP0871440B1 (de) |
JP (3) | JP2000501707A (de) |
AT (1) | ATE320804T1 (de) |
DE (1) | DE69635959T2 (de) |
DK (1) | DK0871440T3 (de) |
ES (1) | ES2260773T3 (de) |
IL (1) | IL124536A (de) |
PT (1) | PT871440E (de) |
WO (2) | WO1997020553A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE320804T1 (de) * | 1995-12-07 | 2006-04-15 | Daniel C Javitt | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme |
US6355681B2 (en) * | 1995-12-07 | 2002-03-12 | Glytech, Inc. | Glycine substitutes and precursors for treating a psychosis |
US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
US6001854A (en) * | 1996-05-31 | 1999-12-14 | Allelix Neuroscience Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
US6191165B1 (en) | 1996-05-31 | 2001-02-20 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
US6416975B1 (en) * | 1998-11-12 | 2002-07-09 | Gliatech, Inc. | Human glycine transporter type 2 |
WO2000062812A1 (en) * | 1999-04-20 | 2000-10-26 | Advocare International Llc | Nutritional composition for improved cognitive performance |
US6551993B1 (en) * | 1999-08-16 | 2003-04-22 | Thomas Jefferson University | Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction |
UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
TWI243173B (en) | 1999-11-17 | 2005-11-11 | Akzo Nobel Nv | Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives |
DK1368336T3 (da) | 2001-02-16 | 2006-10-02 | Allelix Neuroscience Inc | Thiophensubstituerede aminderivater som GlyT-1-inhibitorer |
US20020187544A1 (en) * | 2001-04-05 | 2002-12-12 | Wisconsin Alumni Research Foundation | Uropathogenic E. coli D-serine detoxification operon |
EP1542017A4 (de) * | 2002-07-04 | 2007-07-11 | Mitsubishi Pharma Corp | Verfahren zum untersuchen und diagnostizieren des integrationsfehlfunktionssyndroms |
FR2843590B1 (fr) * | 2002-08-14 | 2007-10-05 | Prestwick Scient Capital Inc | Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique |
US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
US7601740B2 (en) * | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
IL154318A (en) * | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
AU2004233942A1 (en) | 2003-04-30 | 2004-11-11 | H. Lundbeck A/S | Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives |
KR20060066729A (ko) * | 2003-08-21 | 2006-06-16 | 하. 룬트벡 아크티에 셀스카브 | 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 |
CA2547652A1 (en) * | 2003-12-04 | 2005-06-16 | The Research Foundation Of The City University Of New York | Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal |
EP1781279A2 (de) * | 2004-06-11 | 2007-05-09 | Egon Tech | Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels |
WO2006000222A2 (en) * | 2004-06-24 | 2006-01-05 | H. Lundbeck A/S | The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
EP3508201A3 (de) | 2004-08-09 | 2019-10-16 | Enrique Melendez Hevia | Glycin als dietätische zugabe zur verwendung in der behandlung von hautproblemen, die aus zugrundeliegenden kollagenstörungen resultieren |
WO2006066121A2 (en) * | 2004-12-16 | 2006-06-22 | Janssen Pharmaceutica N.V. | Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
US7531572B2 (en) * | 2006-07-28 | 2009-05-12 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
PL2134330T3 (pl) | 2007-03-19 | 2013-10-31 | Acadia Pharm Inc | Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami |
US20090082388A1 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
WO2010053976A2 (en) * | 2008-11-04 | 2010-05-14 | Mclean Hospital Corporation | Drug-enhanced neurofeedback |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
CA2816609A1 (en) * | 2010-11-12 | 2012-05-18 | Promentis Pharmaceuticals, Inc. | S-t-butyl protected cysteine di-peptide analogs and related compounds |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
EP3325444B1 (de) | 2015-07-20 | 2021-07-07 | Acadia Pharmaceuticals Inc. | Verfahren zur herstellung von n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy) phenylmethyl)carbamide und seinem tartrat-salt und seiner polymorphen form c |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
KR102609676B1 (ko) | 2017-06-12 | 2023-12-05 | 글리테크 엘엘씨. | Nmda 길항제 및 d2/5ht2a 또는 선택적 5ht2a 길항제를 이용한 우울증의 치료 |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
CN111491629A (zh) | 2017-11-22 | 2020-08-04 | 康塞特医药品公司 | D-丝氨酸的氘化类似物及其用途 |
IL275968B2 (en) * | 2018-01-10 | 2024-07-01 | Xwpharma Ltd | Ketamine prodrugs, preparations containing them and their uses |
US20220087970A1 (en) * | 2019-01-18 | 2022-03-24 | The Johns Hopkins University | Prevention of anesthetic-induced neurocognitive dysfunction |
BR112022007676A2 (pt) * | 2019-11-18 | 2022-08-09 | Nestle Sa | Composições e métodos para aumentar glutationa para uso na saúde cerebral |
CN117881394A (zh) | 2021-08-13 | 2024-04-12 | 凯瑞康宁生物工程(武汉)有限公司 | 氯胺酮衍生物的药物组合物和口服剂型 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904681A (en) * | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
JPH07103018B2 (ja) * | 1988-09-16 | 1995-11-08 | 武田薬品工業株式会社 | 精神分裂病治療剤 |
JP2757960B2 (ja) * | 1988-10-17 | 1998-05-25 | サントリー株式会社 | (2R,3S,4S)−α−(カルボキシシクロプロピル)グリシン |
US5187171A (en) * | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
US5179085A (en) * | 1989-03-15 | 1993-01-12 | Warner-Lambert Company | N-substituted α-amino acids and derivatives thereof having pharmaceutical activity |
JPH03236315A (ja) * | 1989-12-05 | 1991-10-22 | Nippon Oil & Fats Co Ltd | 抗精神病薬 |
US5260324A (en) * | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
EP0614487A4 (de) | 1991-11-12 | 1995-04-19 | Synaptic Pharma Corp | DNA, die für einen Glycin-Transporter kodiert und Anwendungen dafür. |
US5428069A (en) * | 1993-01-11 | 1995-06-27 | The United States Of America As Represented By The Department Of Health & Human Services | Treating cognition with, aminocyclopropanecarboxylic derivatives |
US5656608B1 (en) * | 1995-02-23 | 2000-09-26 | Novartis Nutrition Ltd | Amino acid compositions and methods of treatment using same |
ATE320804T1 (de) * | 1995-12-07 | 2006-04-15 | Daniel C Javitt | Behandlung negativer und kognitiver symptome der schizophrenie mit antagonisten der glycinaufnahme |
-
1996
- 1996-12-05 AT AT96941518T patent/ATE320804T1/de active
- 1996-12-05 ES ES96941518T patent/ES2260773T3/es not_active Expired - Lifetime
- 1996-12-05 DK DK96941518T patent/DK0871440T3/da active
- 1996-12-05 DE DE69635959T patent/DE69635959T2/de not_active Expired - Lifetime
- 1996-12-05 WO PCT/US1996/019142 patent/WO1997020553A1/en active IP Right Grant
- 1996-12-05 WO PCT/US1996/019141 patent/WO1997020552A1/en active Application Filing
- 1996-12-05 JP JP09521348A patent/JP2000501707A/ja active Pending
- 1996-12-05 PT PT96941518T patent/PT871440E/pt unknown
- 1996-12-05 EP EP96941518A patent/EP0871440B1/de not_active Revoked
- 1996-12-05 IL IL12453696A patent/IL124536A/xx not_active IP Right Cessation
- 1996-12-06 US US08/759,714 patent/US5854286A/en not_active Expired - Lifetime
- 1996-12-06 US US08/759,681 patent/US5837730A/en not_active Expired - Lifetime
-
1998
- 1998-12-16 US US09/212,273 patent/US6162827A/en not_active Expired - Lifetime
-
2009
- 2009-03-18 JP JP2009066534A patent/JP5363152B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-15 JP JP2012251233A patent/JP2013056918A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP5363152B2 (ja) | 2013-12-11 |
US5854286A (en) | 1998-12-29 |
IL124536A0 (en) | 1998-12-06 |
US5837730A (en) | 1998-11-17 |
WO1997020552A1 (en) | 1997-06-12 |
IL124536A (en) | 2001-03-19 |
EP0871440A4 (de) | 1999-01-20 |
US6162827A (en) | 2000-12-19 |
EP0871440B1 (de) | 2006-03-22 |
PT871440E (pt) | 2006-07-31 |
DE69635959T2 (de) | 2006-12-07 |
WO1997020553A1 (en) | 1997-06-12 |
JP2009167205A (ja) | 2009-07-30 |
JP2013056918A (ja) | 2013-03-28 |
JP2000501707A (ja) | 2000-02-15 |
DE69635959D1 (de) | 2006-05-11 |
EP0871440A1 (de) | 1998-10-21 |
ES2260773T3 (es) | 2006-11-01 |
ATE320804T1 (de) | 2006-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0871440T3 (da) | Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister | |
PL323825A1 (en) | Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin | |
ES8602768A1 (es) | Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas. | |
NO911624D0 (no) | Farmasoeytiske forbindelser. | |
TR199900308T2 (xx) | Tiyenopirimidinler | |
DK0535091T3 (da) | Knogleinducerende farmaceutiske formuleringer | |
DE3683528D1 (de) | Tetrapyrrol-therapiemittel. | |
DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
ATE255896T1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
MX9707570A (es) | Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria. | |
HU9602721D0 (en) | Use of serotonin antagonists (5ht3) for treating fibromyalgia | |
UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
IL89278A0 (en) | Tetrazole excitatory amino acid receptor antagonists | |
IE852596L (en) | Peptides active on the cns | |
MD960168A (ro) | Metodă şi compuşi pentru tratamentul infecţiilor virale | |
DK1431391T3 (da) | RANTES-mutanter og terapeutiske anvendelser heraf | |
DE69412178D1 (de) | Apparat zur Behandlung von Lagen | |
ES2094930T3 (es) | Nueva proteina inhibidora de trombina aislada de garrapatas. | |
EA199600048A3 (ru) | N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции | |
CA2239624A1 (en) | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists | |
DK366380A (da) | Anvendelsen af grp og salte deraf | |
ITLE920006V0 (it) | Pannolino in cotone 100% fibra naturale (ecologico) per la prevenzionee cura della displasia congenita dell'anca. | |
MX9504335A (es) | Uso de la sal de amina dietilica de ceruletida en el tratamiento de la psoriasis. |